352 related articles for article (PubMed ID: 30385419)
1. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
2. Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis.
Bahlool AZ; Fattah S; O'Sullivan A; Cavanagh B; MacLoughlin R; Keane J; O'Sullivan MP; Cryan SA
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015371
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary Killing.
Lawlor C; O'Connor G; O'Leary S; Gallagher PJ; Cryan SA; Keane J; O'Sullivan MP
PLoS One; 2016; 11(2):e0149167. PubMed ID: 26894562
[TBL] [Abstract][Full Text] [Related]
4. All-trans Retinoic Acid Augments Autophagy during Intracellular Bacterial Infection.
Coleman MM; Basdeo SA; Coleman AM; Cheallaigh CN; Peral de Castro C; McLaughlin AM; Dunne PJ; Harris J; Keane J
Am J Respir Cell Mol Biol; 2018 Nov; 59(5):548-556. PubMed ID: 29852080
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
6. Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.
Gupta A; Sharma D; Meena J; Pandya S; Sachan M; Kumar S; Singh K; Mitra K; Sharma S; Panda AK; Gupta P; Gupta UD; Misra A
Pharm Res; 2016 Aug; 33(8):1899-912. PubMed ID: 27095353
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb).
Lawlor C; O'Sullivan MP; Rice B; Dillon P; Gallagher PJ; O'Leary S; Shoyele S; Keane J; Cryan SA
J Mater Sci Mater Med; 2012 Jan; 23(1):89-98. PubMed ID: 22183789
[TBL] [Abstract][Full Text] [Related]
8. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.
Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246
[TBL] [Abstract][Full Text] [Related]
9. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
Sharma R; Saxena D; Dwivedi AK; Misra A
Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
[TBL] [Abstract][Full Text] [Related]
10. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP
J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140
[TBL] [Abstract][Full Text] [Related]
11. Single-dose Ag85B-ESAT6-loaded poly(lactic-
Malik A; Gupta M; Mani R; Bhatnagar R
Int J Nanomedicine; 2019; 14():3129-3143. PubMed ID: 31118627
[TBL] [Abstract][Full Text] [Related]
12. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis.
Andreu V; Larrea A; Rodriguez-Fernandez P; Alfaro S; Gracia B; Lucía A; Usón L; Gomez AC; Mendoza G; Lacoma A; Dominguez J; Prat C; Sebastian V; Ainsa JA; Arruebo M
Nanomedicine (Lond); 2019 Mar; 14(6):707-726. PubMed ID: 30734643
[TBL] [Abstract][Full Text] [Related]
13. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
[TBL] [Abstract][Full Text] [Related]
14. Microfluidics produced ATRA-loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models.
Bahlool AZ; Cavanagh B; Sullivan AO; MacLoughlin R; Keane J; Sullivan MPO; Cryan SA
Eur J Pharm Sci; 2024 May; 196():106734. PubMed ID: 38417586
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration.
Thanki K; van Eetvelde D; Geyer A; Fraire J; Hendrix R; Van Eygen H; Putteman E; Sami H; de Souza Carvalho-Wodarz C; Franzyk H; Nielsen HM; Braeckmans K; Lehr CM; Ogris M; Foged C
J Control Release; 2019 Sep; 310():82-93. PubMed ID: 31398360
[TBL] [Abstract][Full Text] [Related]
16. Cytocompatibility and cellular interactions of chondroitin sulfate microparticles designed for inhaled tuberculosis treatment.
Rodrigues S; Cunha L; Kollan J; Neumann PR; Rosa da Costa AM; Dailey LA; Grenha A
Eur J Pharm Biopharm; 2021 Jun; 163():171-178. PubMed ID: 33838263
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis.
Verma RK; Singh AK; Mohan M; Agrawal AK; Verma PR; Gupta A; Misra A
Mol Pharm; 2012 Nov; 9(11):3183-9. PubMed ID: 22978290
[TBL] [Abstract][Full Text] [Related]
19. Loperamide Restricts Intracellular Growth of Mycobacterium tuberculosis in Lung Macrophages.
Juárez E; Carranza C; Sánchez G; González M; Chávez J; Sarabia C; Torres M; Sada E
Am J Respir Cell Mol Biol; 2016 Dec; 55(6):837-847. PubMed ID: 27468130
[TBL] [Abstract][Full Text] [Related]
20. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
